Skip to main content
SpringerLink
Log in

Receptor mediated pathways for interferon action:In vivo implications

  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

High affinity receptors for human interferon (IFN) are a common surface component of human nucleated cells. A model culture system has been used to mark the activation of surface receptors by IFN as the first step in several, possibly separate, pathways of action, some of which depend on the continued presence of IFN. Two types of equilibrium binding can be seen: an initial one of short duration corresponding to receptor activation and a second of longer duration corresponding to activation of a second site by IFN. Various different responses to IFN are seen to be determined by one or other of these equilibria.In vivo, implications are discussed in terms of the pharmacokinetic distribution of IFN, with particular reference to intravenous injection. Desensitization of target cells with respect to late equilibrium effects is seen as a possible consequence of receptor activation against the background of changing IFN concentrationin vivo. A modulating effect of combined IFN species is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Report from the committee on interferon nomenclature, in Gresser I (ed):Interferon 2 1980, p. 97. London, Academic Press (1980).

    Google Scholar 

  2. Weissmann C: The cloning of interferon and other mistakes, in Gresser I (ed):Interferon 3 1981, p. 101. London, Academic Press (1981).

    Google Scholar 

  3. Streuli M., Nagata S, Weissmann C: Not less than three different species of type α (leukocyte) interferon in man: Nucleotide sequence of the cDNA for interferon α2.Science 209, 1343 (1980).

    Article  PubMed  CAS  Google Scholar 

  4. Strander H, Mogensen K E, Cantell K: Production of human lymphoblastoid interferon.J clin Microbiol 1, 116 (1975).

    PubMed  CAS  Google Scholar 

  5. Allen G, Fantes K H, Burke D C, Morser J: Analysis and purification of human lymphoblastoid (Namalwa) interferon using a monoclonal antibody.J gen Virol 63, 207 (1982).

    Article  PubMed  CAS  Google Scholar 

  6. Mogensen K E, Bandu M T, Vignaux F, Aguet M, Gresser I: Binding of125I-labelled human α interferon to human lymphoid cells.Int J Cancer 28, 575 (1981).

    Article  PubMed  CAS  Google Scholar 

  7. Mogensen K E, Bandu M T: Kinetic evidence for an activation step following binding of human interferon alpha-2 to the membrane receptors of Daudi cells.Eur J Biochem 134, 355 (1983).

    Article  PubMed  CAS  Google Scholar 

  8. Mogensen K E, Vignaux F, Gresser I: Enhanced expression of cellular receptors for human interferon α on peripheral lymphocytes from patients with Down's syndrome.FEBS Lett 140, 285 (1982).

    Article  PubMed  CAS  Google Scholar 

  9. Aguet M, Blanchard B: High affinity binding of125I-labelled mouse interferon to a specific cell surface receptor. II. Analysis of binding properites.Virology 115, 249 (1981).

    Article  PubMed  CAS  Google Scholar 

  10. Aguet M, Gresser I, Hovanessian A G, Bandu M T, Blanchard B, Blangy D: Specific high affinity binding of125I-labelled mouse interferon to interferon resistant embryonal carcinoma cellsit vivo.Virology 114, 585 (1981).

    Article  PubMed  CAS  Google Scholar 

  11. Zoon K, Zur Nedden D, Arnheiter H: Specific binding of human α interferon to a high affinity cell surface binding site on bovine kidney cells.J Biol Chem 257, 4695 (1982).

    PubMed  CAS  Google Scholar 

  12. Gresser I, Bandu M T, Brouty-Boyé D, Tovey M: Pronounced antiviral activity of human interferon on bovine and porcine cells.Nature 251, 543 (1974).

    Article  PubMed  CAS  Google Scholar 

  13. Aguet M, Mogensen K E: Interferon receptors, in Gresser I (ed):Interferon 5 1983. London, Academic Press (in press).

  14. Gresser I, Bandu M T, Brouty-Boyé D: Interferon and cell division. IX. Interferon resistant L1210 cells: characteristics and origin.J natn Cancer Inst 52, 553 (1974).

    CAS  Google Scholar 

  15. Aguet M: High affinity binding of125I-labelled mouse interferon to a specific cell surface receptor.Nature 284, 459 (1980).

    Article  PubMed  CAS  Google Scholar 

  16. Tovey M G, Dron M, Mogensen K E, Lebleu B, Mechtil N, Begon-Lours-Guymarho J: Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance.J gen Virol (in press).

  17. Aguet M, Gröbke M, Dreiding P: Various human interferon alpha sub-classes cross-react with common receptors; their binding affinities correlate with their specific biological activities.Virology (in press).

  18. Branca A, Baglioni C: Down-regulation of the interferon receptor.J Biol Chem 257, 13197 (1982).

    PubMed  CAS  Google Scholar 

  19. Adams A, Strander H, Cantell K: Sensitivity of Epstein—Barr virus transformed human lymphoid cell lines to interferon.J gen Virol 28, 207 (1975).

    Article  PubMed  CAS  Google Scholar 

  20. Evinger M, Maeda S, Pestka S: Recombinant human leukocyte interferon produced in bacteria has anti-proliferative activity.J Biol Chem 256, 2113 (1981).

    PubMed  CAS  Google Scholar 

  21. Hilfenhaus J, Damm H, Karges H E, Manthey K F: Growth inhibition of human Daudi cellsin vitro by interferon preparations.Arch Virol 51, 87 (1976).

    Article  PubMed  CAS  Google Scholar 

  22. Streuli M, Hall A, Boll W, Stewart II W E, Nagata S, Weissmann C: Target cell specificity of two species of human inteferon-α produced inEscherischia coli and the hybrid molecules derived from them.Proc natn Acad Sci 78, 2848 (1981).

    Article  CAS  Google Scholar 

  23. Mogensen K E, Bandu M T, Vignaux F, Eid P, Uzé G, Jasmin J C, Gresser I: Etude des récepteurs dans les cellules néoplasiques humaines. I. Nombre des récepteurs à la surface cellulaire de la lignée B-lymphoblastoide Daudi.Pathol Biol 31, 661 (1983).

    Google Scholar 

  24. Eid P, Mogensen K E: Isolated interferon α receptor complexes stabilizedin vitro.FEBS Lett 156, 157 (1983).

    Article  PubMed  CAS  Google Scholar 

  25. Boeynaems J M, Dumont J E:Outlines of Receptor Theory, p. 51. Amsterdam, Elsvier/North-Holland (1980).

    Google Scholar 

  26. Tovey M G: Interferon and cyclic nucleotides, in Gresser I (ed):Interferon 4 1982, p. 33. London, Academic Press (1982).

    Google Scholar 

  27. Tovey M G, Dron M, Gresser I: Interferon enhances the expression of Epstein—Barr virus early antigen in Daudi cells.J gen Vitrol 60, 31–38 (1982).

    Article  CAS  Google Scholar 

  28. Dianzani F, Baron S: Unexpectedly rapid action of human interferon in physiological conditions.Nature 257, 682 (1975).

    Article  PubMed  CAS  Google Scholar 

  29. Friedman R M, Ramseur J M: Inhibition of murine leukemia virus production in chronically infected AKR cells: a novel effect of interferon.Proc natn Acad Sci 71, 3542 (1974).

    Article  CAS  Google Scholar 

  30. Fellous M, Bono R, Hyafil F, Gresser I: Interferon enhances the amount of membrane-bound β2 micro-globulin and its release from human Burkitt cells.Eur J Immunol 11, 524 (1981).

    Article  PubMed  CAS  Google Scholar 

  31. Rosa F, Fellous M, Dron M, Tovey M, Revel M: Presence of an abnormal β2 microglobulin mRNA in Daudi cells: induction by interferon.Immunogenetics 17, 125 (1983).

    Article  PubMed  CAS  Google Scholar 

  32. Yaron M, Yaron I, Gurari-Rotman D, Revel M, Lindner H R, Zor U: Stimulation of prostaglandin E production in cultured human fibroblasts by poly I-C and human interferon.Nature 267, 457 (1977).

    Article  PubMed  CAS  Google Scholar 

  33. Scott G M, Secher D S, Flowers D, Bate J, Cantell K, Tyrell D: Toxicity of interferon.Br Med J 282, 1345 (1981).

    Article  CAS  Google Scholar 

  34. Brouty-Boyé D: Interferon and the reversion of the transformed phenotype.Survey Immunol Res 1, 316 (1982).

    Google Scholar 

  35. Tovey M G, Rochette-Egly C, Kolb J P: Interferon enhancement of natural killer cell cytotoxicity: role of cyclic nucleotides.J Interferon Res 2, 549 (1982).

    PubMed  CAS  Google Scholar 

  36. Fridman W H, Gresser I, Bandu M T, Aguet M, Neuport-Sautes C: Interferon enhances the expression of Fc receptors.J Immunol 124, 2436 (1980).

    PubMed  CAS  Google Scholar 

  37. Huet C, Gresser I, Bandu M T, Lindahl P: Increased binding of concanavalin A to interferon treated murine leukemia L1210 cells.Proc Soc exp Biol Med 147, 52 (1974).

    PubMed  CAS  Google Scholar 

  38. Matsuyama M: Action of interferon on cell membrane of mouse lymphocytes.Exp Cell Res 124, 253 (1979).

    Article  PubMed  CAS  Google Scholar 

  39. Weissmann C, Nagata S, Boll W, Fountoulakis M, Fujisawa A, Fujisawa J, Haynes J, Henco K, Mantei N, Ragg H, Schein C, Schmid J, Shaw G, Streuli M, Taira H, Todokoro K, Weidle U: Structure and expression of human IFN α genes.Phil Trans R Soc Lond B 299, 7 (1982).

    Article  CAS  Google Scholar 

  40. Samuel C E, Knutson G S, Masters P S: Mechanism of interferon action: ability of cloned human type-alpha interferons to induce protein phosphorylation and inhibit virus replication is specified by the host cell rather than the interferon sub-species.J Interferon Res 2, 563 (1982).

    PubMed  CAS  Google Scholar 

  41. Branca A A, Baglioni C: Evidence that type I and type II interferon have different receptors.Nature 294, 768 (1981).

    Article  PubMed  CAS  Google Scholar 

  42. Joshi A R, Sarkar F H, Gupta S L: Interferon receptors: Cross linking of human leukocyte interferon α2 to its receptor on human cells.J Biol Chem 257, 13884 (1982).

    PubMed  CAS  Google Scholar 

  43. Faltenyck C R, Branca A A, McCandless S, Baglioni C: Characterization of an interferon receptor of human lymphoblastoid cells.Proc natn Acad Sci 80, 3269 (1983).

    Article  Google Scholar 

  44. Dedrick R L, Bischoff K B: Species similarities in pharmacokinetics.Federation Proc 39, 54 (1980).

    CAS  Google Scholar 

  45. Cantell K, Pyhälä L, Strander H: Circulating human interferon after intramuscular injection into animals and man.J gen Virol 25, 453 (1974).

    Article  PubMed  CAS  Google Scholar 

  46. Mogensen K E, Cantell K: Production and preparation of human leukocyte interferon.Pharmacol Ther 1, 369 (1977).

    CAS  Google Scholar 

  47. Bocci V, Pacini A, Pessina G P, Bargigli V: Metabolism of interferon.La Ricerca clin Lab 8, 17 (1978).

    CAS  Google Scholar 

  48. Bocci V, Mogensen K E, Muscettola M, Pacini A, Paulesu L, Pessina G P, Skiftas S: Metabolic behaviour of human125I-interferon alpha perfusing rabbit organs.J Lab Clin Med 101, 857 (1983).

    PubMed  CAS  Google Scholar 

  49. Muscettola M, Pacini A, Paulesu L, Pessina G P, Mogensen K E, Skiftas S, Bocci V: Pulmonary catabolism of interferons, in De Mayer E, Galasso G, Schellekens H (eds):The Biology of the Interferon System TNO Congress 1983. Amsterdam, Elsevier/North-Holland (in press).

    Google Scholar 

  50. Habif D V, Lipton R, Cantell K: Interferon crosses blood-brain barrier in monkeys.Proc Soc exp Biol Med 149, 287 (1975).

    PubMed  CAS  Google Scholar 

  51. Cantell K, Pyhälä L: Pharmacokinetics of human leukocyte interferon.J infect Dis 133, A6 (1976).

    PubMed  Google Scholar 

  52. Gresser I: On the mechanisms of the antitumor effects of interferon.Texas Rep Biol Med 41, 582 (1981–82).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d'Oncologie Virale, Institut de Recherches Scientifiques sur le Cancer, BP 8, 94802, Villejuif, France

    K. E. Mogensen, M. -T. Bandu, F. Vignaux, G. Uze & P. Eid

Authors
  1. K. E. Mogensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. -T. Bandu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Vignaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Uze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Eid
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mogensen, K.E., Bandu, M.T., Vignaux, F. et al. Receptor mediated pathways for interferon action:In vivo implications. Med. Oncol. & Tumor Pharmacother. 1, 77–85 (1984). https://doi.org/10.1007/BF02934978

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934978

key words

Search

Navigation